Johnson & Johnson said Tuesday it can produce 20 million doses of the single-shot coronavirus vaccine by late March and has applied for emergency authorization by the Food and Drug Administration.
SANOFI PRODUCING JOHNSON & JOHNSON COVID-19 VACCINES
“Assuming necessary regulatory approvals relating to our manufacturing processes, our plan is to begin shipping immediately upon emergency use authorization, and deliver enough single-doses by the end of March to enable the vaccination of more than 20 million Americans,” Richard Nettles, vice president of medical affairs for Johnson & Johnson’s pharmaceutical unit Janssen, told the House Energy and Commerce subcommittee. Nettles’ remarks were published ahead of the meeting.
The panel of lawmakers began hearing testimony from the five companies with contracts to supply COVID-19 shots to the U.S. — Pfizer, Moderna, Johnson & Johnson, AstraZeneca and Novavax– as the supply of vaccines remains short when compared to the increased demand for the coveted shots.
A Phase 3 trial of the Johnson & Johnson vaccine found that the effectiveness of its shot to combat moderate to severe COVID-19 infections was 72% in the United States, 66% in Latin America and 57% in South Africa, 28 days post-vaccination, according to the pharmaceutical company…